Kwmg LLC raised its position in Pfizer Inc. (NYSE:PFE) by 9.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,698 shares of the biopharmaceutical company’s stock after buying an additional 2,658 shares during the period. Kwmg LLC’s holdings in Pfizer were worth $1,074,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Seaward Management Limited Partnership raised its stake in Pfizer by 5.7% in the second quarter. Seaward Management Limited Partnership now owns 908,421 shares of the biopharmaceutical company’s stock worth $31,985,000 after buying an additional 48,827 shares during the period. Bloom Tree Partners LLC purchased a new stake in Pfizer during the first quarter valued at approximately $35,682,000. State of Alaska Department of Revenue raised its stake in Pfizer by 11.3% in the second quarter. State of Alaska Department of Revenue now owns 371,887 shares of the biopharmaceutical company’s stock valued at $13,093,000 after buying an additional 37,647 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Pfizer by 2.8% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 955,618 shares of the biopharmaceutical company’s stock valued at $33,647,000 after buying an additional 25,855 shares during the last quarter. Finally, Charter Trust Co. raised its stake in Pfizer by 4.3% in the second quarter. Charter Trust Co. now owns 377,918 shares of the biopharmaceutical company’s stock valued at $13,306,000 after buying an additional 15,510 shares during the last quarter. 69.48% of the stock is owned by institutional investors.
Shares of Pfizer Inc. (NYSE:PFE) traded up 0.86% on Friday, reaching $31.69. The company’s stock had a trading volume of 10,452,948 shares. The stock has a market capitalization of $192.31 billion, a P/E ratio of 31.82 and a beta of 0.90. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The company has a 50 day moving average of $32.01 and a 200 day moving average of $34.15.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.62 by $0.01. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The business had revenue of $13.05 billion for the quarter, compared to analyst estimates of $13.05 billion. During the same period in the prior year, the company earned $0.60 EPS. The company’s revenue was up 7.9% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post $2.41 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.79%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is presently 106.20%.
Several analysts have commented on the stock. Argus reissued a “buy” rating and set a $39.00 price target on shares of Pfizer in a research report on Sunday, August 28th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Citigroup Inc. reissued a “neutral” rating and set a $37.00 price target on shares of Pfizer in a research report on Wednesday, August 3rd. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target for the company in a research report on Tuesday, August 2nd. Finally, Jefferies Group set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, August 1st. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $37.73.
In related news, insider Albert Bourla sold 18,390 shares of the company’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $30.05, for a total transaction of $552,619.50. Following the transaction, the insider now owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Anthony J. Maddaluna sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $33.00, for a total value of $330,000.00. Following the transaction, the insider now directly owns 112,087 shares in the company, valued at approximately $3,698,871. The disclosure for this sale can be found here. Corporate insiders own 0.07% of the company’s stock.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.